# Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

> **NCT04915183** · PHASE2 · RECRUITING · sponsor: **National Institute on Deafness and Other Communication Disorders (NIDCD)** · enrollment: 224 (estimated)

## Conditions studied

- Hearing Loss
- Head and Neck Cancer

## Interventions

- **OTHER:** Placebo
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT04915183
- **Lead sponsor:** National Institute on Deafness and Other Communication Disorders (NIDCD)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2028-08-01
- **Final completion:** 2030-08-31
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915183, "Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04915183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*